Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Dapiglutide

Stage Phase 2Stale

Sponsor Zealand Pharma

Route injection

Class GLP-1 RA

Mechanism This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist,

Sources

registry, as of 2024-12-05Stale

https://clinicaltrials.gov/study/NCT05788601

Dapiglutide for the Treatment of Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor University Hospital, Gentofte, Copenhagen. Enrollment 54. Conditions Obesity; Inflammation. This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly

ClinicalTrials.gov NCT05788601 protocol and results modules

registry, as of 2025-05-06Stale

https://clinicaltrials.gov/study/NCT06758583

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zealand Pharma. Enrollment 30. Conditions Overweight and Obesity. This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and

ClinicalTrials.gov NCT06758583 protocol and results modules

Studies

DREAM

Registry NCT05788601

Phase Phase 2

Status Active, not recruiting

Enrollment 54

Start 2023-04-27

Primary completion 2024-04-24

Study completion 2025-08-15

Placebo (4 mg and 6 mg)

Dose 4 mg and 6 mg

Regimen once weekly

Weeks 12

Population Obesity; Inflammation

4 mg dapiglutide

Dose 4 mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Obesity; Inflammation

6 mg dapiglutide

Dose 6 mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Obesity; Inflammation

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Registry NCT06758583

EudraCT 2024-516901-21

Phase Phase 1

Status Completed

Enrollment 30

Start 2024-12-23

Primary completion 2025-04-12

Study completion 2025-04-25

Catalyst Primary completion. 2025-04-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Dapiglutide 10 mg/mL

Dose 10 mg

Population Overweight and Obesity

Dapiglutide 25 mg/mL

Dose 25 mg

Population Overweight and Obesity